Publicacións nas que colabora con Javier Pemán García (22)

2024

  1. Corrigendum to “Safety and effectiveness of isavuconazole in real-life non-neu tropenic patients” [International Journal of Infectious Diseases 144 (2024) 107070] (International Journal of Infectious Diseases (2024) 144, (S1201971224001413), (10.1016/j.ijid.2024.107070))

    International Journal of Infectious Diseases

  2. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients

    International Journal of Infectious Diseases, Vol. 144

2023

  1. Critical appraisal beyond clinical guidelines for intraabdominal candidiasis

    Critical Care, Vol. 27, Núm. 1

  2. IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients

    Journal of Fungi, Vol. 9, Núm. 6

2022

  1. Erratum: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies (Open Forum Infect Dis (2021) 8:6 DOI: 10.1093/ofid/ofab250)

    Open Forum Infectious Diseases

2021

  1. Early Stepdown from Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

2020

  1. An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 730-737

  2. Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two prospective cohorts

    Critical Care, Vol. 24, Núm. 1

2019

  1. Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 8, pp. 535-541

  2. Usefulness of guideline recommendations for prognosis in patients with candidemia

    Medical mycology, Vol. 57, Núm. 6, pp. 659-667

2017

  1. Epidemiology and prognosis of candidaemia in elderly patients

    Mycoses, Vol. 60, Núm. 12, pp. 808-817

  2. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

2016

  1. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8

  2. Risk factors, clinical presentation and prognosis of mixed candidaemia: a population-based surveillance in Spain

    Mycoses, Vol. 59, Núm. 10, pp. 636-643

2015

  1. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9

  2. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

    Journal of Infection, Vol. 71, Núm. 3, pp. 385-394

  3. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 21, Núm. 5, pp. 491.e1-491.e10

2014

  1. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 11, pp. 3134-3141

  2. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: A population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 20, Núm. 4

2011

  1. Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 6, pp. 435-454